ASN's Mission

ASN leads the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge, and advocating for the highest quality care for patients.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on Twitter

Kidney Week

Abstract: SA-PO927

Incidence of Cardiovascular Events and Mortality in Korean Patients with CKD: Results from KNOW-CKD Cohort

Session Information

Category: CKD (Non-Dialysis)

  • 2102 CKD (Non-Dialysis): Clinical, Outcomes, and Trials

Authors

  • Ryu, Hyunjin, Seoul National University Hospital, JongNo-Gu, seoul, Korea (the Republic of)
  • Kim, Jayoun, Seoul National University Hospital, JongNo-Gu, seoul, Korea (the Republic of)
  • Kang, Eunjeong, Seoul National University Hospital, JongNo-Gu, seoul, Korea (the Republic of)
  • Kang, Minjung, Seoul National University Hospital, JongNo-Gu, seoul, Korea (the Republic of)
  • Hong, Yeji, Seoul National University Hospital, JongNo-Gu, seoul, Korea (the Republic of)
  • Ahn, Curie, Seoul National University Hospital, JongNo-Gu, seoul, Korea (the Republic of)
  • Oh, Kook-Hwan, SNU College of Medicine, Seoul, Korea (the Republic of)

Group or Team Name

  • KNOW-CKD Study Group
Background

There are lack of studies regarding the incidence of major adverse cardiovascular events (MACE) in Asian pre-dialysis population. This study was conducted to analyze the incidences of MACE and death in Korean chronic kidney disease (CKD) population, using the data from a multicenter prospective cohort.

Methods

This is a longitudinal analysis from a multicenter prospective cohort study, entitled KNOW-CKD. Among a total 2,238 patients enrolled, 59 patients without follow-up data were excluded and, finally, 2,179 patients were included. MACE was defined as any of the cardiovascular events occurred during the follow-up. The composite outcome was defined as MACE and all-cause death.

Results

Mean age was 53.6±12.2 years and 38.7% were female. At enrollment, mean eGFR was 53.2±30.7 ml/min/1.73m2 and the prevalence of cardiovascular disease and diabetes were 6.0% and 33.4%, respectively. During median 4.1 years of follow-up, the incidences of MACE, death and composite outcome were 17.2, 9.6 and 24.5 per 1,000 patient-year (PY). All outcome incidences were higher in diabetic patients compared to non-diabetics (p<0.001). The incidence rate increased as CKD stages advanced, for MACE (p=0.001), death (p<0.001) and composite outcomes (p<0.001). In the multivaraite regression model, CKD stage G4 and G5 showed increased HR of 2.5 and 3.2 for MACE compared to G1 adjustment for age and sex. However when other confounding factors were adjusted, the significance disappeared. For the composite outcome, CKD stage G4 and G5 showed significant increased HR of 2.9 and 4.3 over G1, even after other confounding factors were adjusted. When the incidence rate of composite outcome was compared to general population using National Health Insurance service – National, sample cohort, this CKD population had increased HR of 1.5 (CI 1.31-1.72, p<0.001) compared to general population.

Conclusion

The incidence rate of MACE, death and composite outcome in Korean non-dialysis CKD patients were 17.2, 9.6 and 24.5 per 1,000 PY, respectively, which were similar to Japan cohort data but lower than western cohorts data.

Incidence of outcomes according to CKD stages

Funding

  • Government Support - Non-U.S.